ClinicalTrials.gg
RecruitingNCT06634290HipOsGalUpdated Sep 2, 2026

Influence of Cemented Cephalic Augmentation on the Outcome of Intramedullary Nailing in Pertrochanteric Hip Fractures

An interventional study of intramedullary nailing augmentation and intramedullary nailing in Hip Fracture of Intertrochanteric Type, sponsored by Diego Matías Domínguez Prado. Recruiting at 6 sites in Spain. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Diego Matías Domínguez Prado · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
314
Allocation
Randomized
Ages
75 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Hip Fractures with a site in Spain — 10 open to participants now, 10 under way, none of them phase 3. Hip Fractures · Spain.

Planned enrollment
10th of 38
314 · median 168
Started
2024
with 5 others
No phase
22 of 49
8 open now
Registered
43rd of 49
by date

Among the 49 studies in Hip Fractures with a site in Spain, this one is the 10th largest by planned enrollment of the 38 interventional ones that give a count, is one of 6 that started in 2024, is one of 22 with no phase, and was the 43rd registered.

Hip Fractures

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

Browse Hip Fractures studies →

Open to participants now

10 of the 49 studies in Hip Fractures with a site in Spain are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: 75 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Hip Fractures with a site in Spain, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if small modifications in the surgical technique for the treatment of some kind of hip fractures, improve the result of the surgery. This small modification includes the addition of surgical bone cement to part of the intramedullary nail used in the surgery, to find out if it provides more stability to the construct and represents an improvement in the surgery result.

The main question it aims to answer is:

Does the addition of bone cement produces a decrease in complications related to mechanical failure of the implant used in the surgery and a decrease in the need for re-operation?

Researchers will compare adding this bone cement to the standard surgical technique without it.

Patients will:

  • Be randomly assigned to a group that will have surgery following standard protocol or to a group that will have surgery following standard protocol but adding bone cement to the construct.
  • Receive standard care for these fractures during hospitalization and posterior follow-up checkups for a year.
Read the detailed description

Hypothesis

The hypothesis of the study assumes that cephalic augmentation with polymethylmethacrylate cement of the intramedullary nail in the surgical treatment of pertrochanteric hip fractures due to fragility, produces a decrease in complications in relation to mechanical failure of the implant and a decrease in the re-operation rate.

Objectives

The main objective seeks to compare the mechanical failure rates of the implant between intramedullary nailing with and without cephalic augmentation with polymethylmethacrylate cement.

The secondary objectives are to compare the perioperative, 1-month, and 1-year mortality rates of patients treated with intramedullary nailing with and without cephalic augmentation and to evaluate the safety of the surgical technique.

Design

For these purposes, a multicenter, controlled, randomized, single-blind, parallel groups, clinical trial will be carried out.

Participants

Patients over 75 years old, diagnosed with pertrochanteric hip fracture due and requiring surgical intervention, will be eligible for inclusion in the study. All patients will receive surgical treatment using the intramedullary nailing technique, which is the current gold standard treatment for this type of fractures.

Recruitment

Almost all patients who suffer a hip fracture require urgent attention for this process, as well as hospital admission. From the first moment of admission through the emergency room or during the time of hospitalization prior to surgery, the patient and/or their legal representative, will receive pertinent information about the diagnosis, prognosis and treatment of this pathology by and Orthopedic Surgeon.

At the same time that they receive this information, either the principal investigator, or one of the collaborating researchers, will additionally provide information about the study and will recruit patients to participate in it. Prior to the surgery, informed consent will be granted to participate in the research study and the corresponding documents will be signed, along with the usual surgical informed consent used in each institution for this specific pathology,

Given the characteristics of this pathology and the benefit it represents in terms of functional recovery and improved survival, if the surgical intervention is performed in the first 48 hours from the occurrence of the fracture, in some of the patients participating in the study, it may be the case that the operation is performed in less than 24 hours from the acceptance and signing of the informed consent.

Randomization

The patients included in the study will be randomly distributed into two groups, experimental and control. The experimental or CEMENT group will include patients treated with intramedullary nailing WITH cephalic augmentation, and the control or NO CEMENT group will include patients treated with intramedullary nailing WITHOUT cephalic augmentation. Once participation in the study has been accepted and the informed consents have been signed, the randomization process will proceed in the different groups as follows.

The use of a centralized computer system that generates the randomization sequence and performs the registration of the participants, concealment of the randomization sequence and group allocation, is currently the most recommended procedure for conducting clinical trials. For this study, the OxMaR computer system (acronym for Oxford Minimization and Randomization) was used. Each investigator will assign a code to each recruited patient that is recorded in the online randomization form, along with the type of fracture and the patient's sex, which are included as minimization variables.

Description of the intervention

Once the participants have been recruited for the study and have been randomly assigned to the experimental or control group, the surgical intervention will be carried out following the principles of usual clinical practice.

The patient will be operated by an orthopedic surgeon hospital following the usual protocol of the hospital and surgical technique. The implant used will be in all cases an intramedullary nail. Depending on whether the patient has been included in the experimental or control group, surgery will be performed by adding augmentation with polymethylmethacrylate cement to the cephalic component or not.

Regarding blinding, the patient will remain blind to the assignment to one group or another and only the surgeon and the researchers will know the group to which they have been assigned to, given that cement augmentation is easily identifiable for them in a standard radiological control taken during follow-up.

The rest of the follow-up will follow the usual clinical practice during hospital admission and subsequently on an outpatient basis, with controls in outpatient clinics at one month, three months, six months and one year post-intervention. A radiological control will be taken in all follow-ups. Both the clinical follow-up by the surgeon and the radiological follow-up are the same as those carried out in normal clinical practice for this type of pathology. No greater number of visits, consultations, complementary tests, procedures or additional participation are required from the patient for participating in the study.

03

Conditions studied

  • Hip Fracture of Intertrochanteric Type

Browse trials for

Keywords

  • hip fracture
  • osteosynthesis
  • intramedullary nailing
  • bone cement augmentation
04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 75 years of age or older.
  • Diagnosis with a pertrochanteric fragility fracture.
  • for participation in the study.

Exclusion criteria

Exclusion Criteria:

  • Not meeting the inclusion criteria described above.
  • Refusal of the patient or his/her legal representative to participate in the study.
  • Diagnosis with hip fracture of subtypes other than 31A1, 31A2, 31A3 and 31B3 of AO-OTA classification.
  • Bilateral hip fractures in the same episode.
  • Suffering from previous medical pathologies or comorbidities that contraindicate surgical intervention and indicate conservative management of the fracture.
  • Performing a surgical technique different from intramedullary nailing or using a surgical implant different from that used in the present study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
314 participants (estimated)

Study arms

  • Experimental
    Cemented

    Patients diagnosed of pertrochanteric hip fracture treated with intramedullary nailing WITH cephalic augmentation using bone cement

    Device: intramedullary nailing augmentation

  • Active comparator
    Not Cemented

    Patients diagnosed of pertrochanteric hip fracture treated with intramedullary nailing WITHOUT cephalic augmentation

    Device: intramedullary nailing

Interventions

  • Deviceintramedullary nailing augmentation

    Treatment of pertrochanteric hip fractures with intramedullary nailing with cephalic augmentation with bone cement

    Also known as: Osteosynthesis

  • Deviceintramedullary nailing

    Treatment of pertrochanteric hip fractures with intramedullary nailing without cephalic augmentation

    Also known as: osteosynthesis

06

What researchers measure

Primary outcomes

  1. Mechanical failure rate of the implant

    Defined as the intolerable loss of reduction of the fracture and the failure of osteosynthesis due to breakage or disassembly of the implant used, which requires surgical reintervention.

    Time frame: From date of surgery until the date of mechanical failure diagnosis, assessed up to 52 weeks

Secondary outcomes

  1. Perioperative mortality rate

    Proportion of participants who die compared to the total participants during hospital stay, assessed up to a maximum of 7 days

    Time frame: From date of surgery until the date of hospital discharge, assessed up to a maximum of 7 days

  2. One-month mortality rate

    Proportion of participants who die compared to the total participants during a period of 30 days

    Time frame: From date of surgery up to 30 days

  3. One-year mortality rate

    Proportion of participants who die compared to the total participants during a period of 52 weeks

    Time frame: From date of surgery up to 52 weeks

07

Study locations

6 of 6 sites recruiting
  • Hospital de Monforte de Lemos
    Monforte de Lemos, Lugo 27400, Spain
    Recruiting
  • Hospital de Verin
    Verín, Ourense 32600, Spain
    Recruiting
  • Complexo Hospitalario Universitario de Vigo
    Vigo, Pontevedra 36312, Spain
    Recruiting
  • Hospital do Salnes
    Vilagarcía de Arousa, Pontevedra 36619, Spain
    Recruiting
  • Complexo Hospitalario Universitario de Ourense
    Ourense, 32005, Spain
    Recruiting
  • Complexo Hospitalario Pontevedra
    Pontevedra, 36071, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All collected IPD. Anonymized.

Supporting information: Study protocol, Informed consent form

Time frame: Starting 3 months after publication of results

Access criteria: Researchers who wish to access data for meta-analysis. Data sharing must be approved by principal research who can be contacted by e-mail.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 27 months after the start.

Of 221 non-industry interventional studies with no phase under Hip Fractures, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 55. This study's planned 27 months is close to that.

Counting every sponsor, half of 237 studies reached it within 29 months; a quarter within 10 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2024
First posted
Oct 9, 2024
StartActual
Sep 30, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06634290
Lead sponsor
Diego Matías Domínguez Prado
Responsible party
Diego Matías Domínguez Prado (Specialist in Orthopedic Surgery and Traumatology, PhD, Fundacin Biomedica Galicia Sur) — Sponsor-investigator
First posted
Oct 9, 2024
Start date
Sep 30, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 2, 2026

Study contacts

Diego Matias Dominguez Prado, MD, PhD
Contact
diego.matias.dominguez.prado@sergas.es
34+ 670462170
Diego Matias Dominguez Prado, MD, PhD
principal investigator · Complexo Hospitalario de Ourense

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion